SinoMab BioScience Limited — Board/Management Information 2021

Dec 17, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [29 x 44] intentionally omitted <==

==> picture [29 x 44] intentionally omitted <==

SinoMab BioScience Limited 中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability) (Stock code: 3681)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

This announcement is made pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ‘‘Listing Rules’’).

The board (the ‘‘Board’’) of directors (the ‘‘Director(s)’’) of SinoMab BioScience Limited (the ‘‘Company’’, together with its subsidiaries, the ‘‘Group’’) hereby announces that Mr. Lei SHI (石磊) (‘‘Mr. Shi’’) has been appointed as a non-executive Director with effect from 17 December 2021 for a term of three years, subject to re-election and retirement as required by the articles of association of the Company. The biographical details of Mr. Shi are as follows.

Mr. Shi, aged 35, is currently a deputy general manager and secretary of the board of directors of Hainan Haiyao Co., Ltd. (海南海藥股份有限公司). From July 2013 to May 2015, Mr. Shi served as an intellectual property specialist and a senior manager of intellectual property research center of China Institute of Marine Technology & Economy of China State Shipbuilding Corporation (中國船舶工業綜合技術經濟研究院). From May 2015 to July 2019, he served as a senior legal manager of the policy and regulation department of China State Shipbuilding Corporation (中國船舶工業集團有限公司). From July 2019 to September 2021, Mr. Shi served as a vice director and the director of legal affairs department of Xinxing Jihua Pharmaceutical Holdings Co., Ltd. (新興際華醫藥控股 有限公司).

Mr. Shi obtained a master’s degree in civil and commercial law from Beijing University of Chemical Technology in 2013.

Save as disclosed above, as at the date of this announcement, Mr. Shi (i) is not interested in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) is independent from and has no relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; (iii) has not held any other major appointments or qualifications or positions with the Company or other members of the Group; and (iv) has not held any directorship in any other listed public companies in the past three years.

• For identification purposes only

– 1 –

The Company will enter into a letter of appointment with Mr. Shi. The initial length of services will commence from the date of appointment for a term of three years. Mr. Shi will not receive any remuneration from the Company for being a non-executive Director.

Save as disclosed above, there is no information which is discloseable nor is Mr. Shi involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters concerning Mr. Shi that need to be brought to the attention of the shareholders of the Company.

By Order of the Board SinoMab BioScience Limited Dr. Shui On LEUNG Executive Director, Chairman and Chief Executive Officer

Hong Kong, 17 December 2021

As at the date of this announcement, the executive Director is Dr. Shui On LEUNG, the nonexecutive Directors are Dr. Haigang CHEN, Mr. Xun DONG, Mr. Senlin LIU, Ms. Wenyi LIU, Ms. Jie LIU and Mr. Lei SHI, and the independent non-executive Directors are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.

– 2 –